---
title: "NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295819565.md"
description: "NeuroSense Therapeutics outlined plans for its Phase 3 ALS trial (PARAGON), seeking non-dilutive funding due to financing delays. The company aims to file for PrimeC in Canada by December 2026 and address Nasdaq compliance issues, potentially via a reverse split. While management highlights operational momentum, Spark AI rates NRSN as Neutral due to weak financials and unfavorable technicals, contrasting with an analyst Buy rating."
datetime: "2026-08-13T15:17:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295819565.md)
  - [en](https://longbridge.com/en/news/295819565.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295819565.md)
---

# NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts

Neurosense Therapeutics Ltd. ( (NRSN) ) has issued an update.

NeuroSense Therapeutics has released a CEO letter dated August 13, 2026, outlining preparations for PARAGON, its pivotal Phase 3 trial of PrimeC in ALS, following U.S. FDA clearance to enroll about 300 participants primarily in the United States. Management emphasized that financing for this large study has taken longer than expected and said it is pursuing a mix of strategic investors, pharma partners, grants and other non-dilutive funding, with senior executives having invested personal capital in April 2026.

The company is simultaneously seeking to capitalize on existing Phase 2b PARADIGM data by preparing a New Drug Submission for PrimeC in Canada, targeted for December 2026, while evaluating additional territories where current data may support regulatory paths. NeuroSense also highlighted active strategic partnership discussions and detailed steps to resolve Nasdaq listing deficiencies, including a potential reverse share split authorization, signaling both operational momentum around PrimeC and ongoing execution and funding risks for shareholders.

The most recent analyst rating on (NRSN) stock is a Buy  
with a $9.00 price target.  
To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock,  
see the NRSN Stock Forecast page.

**Spark’s Take on NRSN Stock**

According to Spark, TipRanks’ AI Analyst, NRSN is a Neutral.

The score is primarily held down by weak financial performance (pre-revenue, ongoing losses, negative free cash flow, and negative equity). Technicals are also unfavorable with the price below key moving averages and a negative MACD, though RSI suggests the stock is oversold. Valuation support is limited due to negative earnings and no dividend.

To see Spark’s full report on NRSN stock,  
click here.

**More about Neurosense Therapeutics Ltd.**

NeuroSense Therapeutics Ltd. is a late-clinical stage biotechnology company developing novel, disease-modifying treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. Its lead oral combination therapy, PrimeC, targets multiple biological pathways such as neuroinflammation, oxidative stress and dysregulated iron metabolism, and has shown promising Phase 2b data suggesting meaningful slowing of ALS progression and biomarker effects.

**Average Trading Volume:** 225,414

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $17.92M

Find detailed analytics on NRSN stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [NRSN.US](https://longbridge.com/en/quote/NRSN.US.md)
- [NRSNW.US](https://longbridge.com/en/quote/NRSNW.US.md)

## Related News & Research

- [NeuroSense announces shareholder letter availability](https://longbridge.com/en/news/295808294.md)
- [NeuroSense Therapeutics publishes CEO shareholder letter on Phase 3 PrimeC plans](https://longbridge.com/en/news/295817302.md)
- [The AI boom has echoes of Enron — but that might be okay, a tech guru says](https://longbridge.com/en/news/296021200.md)
- [NMRA: Advancing brain-penetrant therapies with strong early results for major CNS and metabolic diseases](https://longbridge.com/en/news/295926732.md)
- [Originalis AI Founding Engineer Ujjwal Jain Unveils AI System Processing Over 645,000 VC Email Threads](https://longbridge.com/en/news/296065185.md)